Anúncio
Anúncio

ABUS

ABUS logo

Arbutus Biopharma Corporation Common Stock

4.62
USD
Patrocinado
-0.04
-0.75%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

4.69

+0.07
+1.60%

Relatórios de Lucros ABUS

Rácio de surpresa positiva

ABUS separação 22 de 40 últimas estimativas.

55%

Próximo Relatório

Data do Próximo Relatório
25 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$714.00K
/
-$0.03
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+34.97%
/
-25.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-54.64%
/
-57.14%

Arbutus Biopharma Corporation Common Stock earnings per share and revenue

On 13 de nov. de 2025, ABUS reported earnings of -0.04 USD per share (EPS) for Q3 25, missing the estimate of -0.03 USD, resulting in a -26.58% surprise. Revenue reached 529.00 mil, compared to an expected 1.29 milhão, with a -59.06% difference. The market reacted with a -5.79% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.03 USD, with revenue projected to reach 714.00 mil USD, implying an diminuir of -25.00% EPS, and aumentar of 34.97% in Revenue from the last quarter.
FAQ
For Q3 2025, Arbutus Biopharma Corporation Common Stock reported EPS of -$0.04, missing estimates by -26.58%, and revenue of $529.00K, -59.06% below expectations.
The stock price moved down -5.79%, changed from $4.84 before the earnings release to $4.56 the day after.
The next earning report is scheduled for 25 de mar. de 2026.
Based on 5 analistas, Arbutus Biopharma Corporation Common Stock is expected to report EPS of -$0.03 and revenue of $714.00K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio